An Fc-engineered anti-PD-L1 mAb that lacks FcγR engagement has shown tumor regression in RCC, with a 12% of objective response rate, 41% stable disease lasting at least 24 weeks and 53% of progression-free survival at 24 weeks [4]. The gene discussed is CD274; the disease is neoplasm.